公开(公告)号：US20200157507A1

公开(公告)日：2020-05-21

申请号：US16611359

申请日：2018-05-02

申请人： PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY

发明人： Tamihide Matsunaga ,  Takahiro Iwao ,  Daichi Onozato ,  Isamu Ogawa

IPC分类号： C12N5/071 ,  G01N33/50 ,  A61L27/38

摘要： An object of the present invention is to prepare a functional intestinal organoid from pluripotent stem cells. An intestinal organoid is prepared from pluripotent stem cells, by the following steps (1) to (4): (1) differentiating pluripotent stem cells into endoderm-like cells; (2) differentiating the endoderm-like cells obtained in step (1) into intestinal stem cell-like cells; (3) culturing the intestinal stem cell-like cells obtained in step (2) to form spheroids; and (4) differentiating the spheroids formed in step (3) to form an intestinal organoid, the step including culture in the presence of a MEK1/2 inhibitor, a DNA methylation inhibitor, a TGF-β receptor inhibitor, and a γ-secretase inhibitor, in addition to an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator.

公开(公告)号：US11859212B2

公开(公告)日：2024-01-02

申请号：US16611359

申请日：2018-05-02

申请人： PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY

发明人： Tamihide Matsunaga ,  Takahiro Iwao ,  Daichi Onozato ,  Isamu Ogawa

IPC分类号： C12N5/071 ,  G01N33/50 ,  A61L27/38

CPC分类号： C12N5/0679 ,  A61L27/3834 ,  A61L27/3882 ,  A61L27/3895 ,  G01N33/5082 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/998 ,  C12N2501/999 ,  C12N2503/04 ,  C12N2506/45 ,  C12N2513/00 ,  C12N2533/70

摘要： An object of the present invention is to prepare a functional intestinal organoid from pluripotent stem cells. An intestinal organoid is prepared from pluripotent stem cells, by the following steps (1) to (4): (1) differentiating pluripotent stem cells into endoderm-like cells; (2) differentiating the endoderm-like cells obtained in step (1) into intestinal stem cell-like cells; (3) culturing the intestinal stem cell-like cells obtained in step (2) to form spheroids; and (4) differentiating the spheroids formed in step (3) to form an intestinal organoid, the step including culture in the presence of a MEK1/2 inhibitor, a DNA methylation inhibitor, a TGF-β receptor inhibitor, and a γ-secretase inhibitor, in addition to an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator.